華住(01179.HK)中績轉賺逾20億人幣 惟股價回吐一成失250天線
華住集團-S(01179.HK)中績虧轉賺逾20億人民幣兼調高全年收入預測。然而,投資者藉好消息先行獲利,該股扭三連漲,一舉失守五條移動平均線(250天線為32.97元),最低見31.95元,現報32.45元,回吐10%,成交增至363萬股,涉資1.17億元;華住(HTHT.US)昨晚於ADR股價跌5.4%收42.49美元。
華住集團公布中期業績賺20.05億元人民幣(下同),扭轉去年同期蝕9.8億元,總收入按年增加65%至100.1億元。單計次季也轉賺10.15億元(去年同期蝕3.5億元)。同時,上調全年收入預測指引至增長48%-52%,原先預計僅增長42%-46%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.